Hristijan Duma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hristijan Duma has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hristina Breshkovska
University Clinic of Dermatology, SS Cyril and Methodius University, 1000 Skopje, North Macedonia
2 shared publications - Ivana Dohcheva Karajovanov
University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
2 shared publications - Silvija Duma
University Clinic of Dermatovenerology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Suzana Nikolovska
University Clinic of Dermatovenerology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
2 shared publications - Ana Trpeska-Boshoska
University Clinic of Ophthalmology, University Ss Cyril and Methodius, Skopje, Republic of North Macedonia
1 shared publication - Andrijana Gjorgjeska
University Clinic for Plastic and Reconstructive Surgery, Ss Cyril and Methodius University of Skopje, Skopje, Republic of North Macedonia
1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 56-60
Toxic Epidermal Necrolysis: Case Report and Review
BACKGROUND: Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum. CASE PRESENTATION: A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months. CONCLUSION: TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.
- 12 March 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 56-60
Open AccessToxic Epidermal Necrolysis: Case Report and Review
BACKGROUND: Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse drug reactions primarily caused by drugs. Characterized by fever, prodromal symptoms, and extensive epidermal sloughing with mucous membrane involvement (>90%), they are collectively termed epidermal necrolysis and are considered a disease continuum. CASE PRESENTATION: A 65-year-old man presented with widespread erythema and distinctive target-like lesions, accompanied by ruptured flaccid vesicles on the extremities. Following a 4-week carbamazepine treatment for a previous cerebrovascular insult, hematological analysis revealed abnormalities. A multidisciplinary team, including a neurologist, endocrinologist, and ophthalmologist, prescribed a 3-day course of intravenous immunoglobulin at 0.5 g/kg and an initial dose of 300 mg prednisolone for 3 days, supported by additional therapy. Discharged after 3 weeks, the rash completely resolved within 2 months. CONCLUSION: TEN, a severe mucocutaneous condition with a 30% mortality rate, often results from drug exposure. Swift identification of the causative drug is crucial for optimal outcomes. Treatment primarily includes discontinuing the offending drug and offering supportive care for mucocutaneous lesions. A multidisciplinary approach is vital based on organ system involvement. The effectiveness of pharmacological treatments, such as intravenous immunoglobulin and corticosteroids, is continually under evaluation.
- Open Access
- 23 January 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 7-12
Drug Rash with Eosinophilia and Systemic Symptoms Syndrome: Case Report and Literature Review
BACKGROUND: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is a rare, potentially life-threatening, drug-induced hypersensitivity reaction. This condition is characterized by a range of symptoms, including cutaneous reaction, hematologic abnormalities, lymphadenopathy, and potential involvement of internal organs. Most DRESS cases are associated with certain medications such as antiseizure drugs, allopurinol, antibacterial sulfonamides, minocycline, and vancomycin. CASE PRESENTATION: We presented a case of 70-year-old women exhibiting maculopapular rash affecting the face, abdomen, and extremities. She experienced generalized pruritus, along with ulcerative crusty lesions on the mouth and mucopurulent conjunctivitis, all of which had persisted for 1 week. She was recently diagnosed with hyperuricemia and had been undergoing treatment with allopurinol for 4 weeks. During her hospital stay, the rash intensified, and there was a worsening involvement of the mucosa in the oral and ocular area. Allopurinol was promptly discontinued, and the patient was prescribed a daily dose of 100 mg prednisolone, gradually tapering off over a 2-month period. Additionally, the treatment included anticoagulants, antibiotics, local application of mild steroid emulsions, antiseptic, and antifungal therapy for the oral mucosa. Antibiotic solutions and natural tear eye drops were used. Over the 2-month period, the rash completely resolved, and the liver enzymes returned to normal levels. CONCLUSION: DRESS syndrome is an unpredictable drug-induced reaction identified by symptoms such as rash, fever, lymphadenopathy, and potential internal organ involvement. Allopurinol is among the medications associated with this condition, particularly when there is a reduced renal clearance and simultaneous use of thiazide diuretics. Prompt withdrawal of the causative drug is the universally accepted approach to manage drug-induced hypersensitivity reactions. The use of systemic corticosteroids can reduce symptoms of delayed hypersensitivity reactions. However, the absence of randomized controlled trials leaves uncertainty about the necessity of administering steroids, sparking a controversial debate regarding their use in such cases.
- 23 January 2024
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Immunology
- Vol. 7, 7-12
Open AccessDrug Rash with Eosinophilia and Systemic Symptoms Syndrome: Case Report and Literature Review
BACKGROUND: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome is a rare, potentially life-threatening, drug-induced hypersensitivity reaction. This condition is characterized by a range of symptoms, including cutaneous reaction, hematologic abnormalities, lymphadenopathy, and potential involvement of internal organs. Most DRESS cases are associated with certain medications such as antiseizure drugs, allopurinol, antibacterial sulfonamides, minocycline, and vancomycin. CASE PRESENTATION: We presented a case of 70-year-old women exhibiting maculopapular rash affecting the face, abdomen, and extremities. She experienced generalized pruritus, along with ulcerative crusty lesions on the mouth and mucopurulent conjunctivitis, all of which had persisted for 1 week. She was recently diagnosed with hyperuricemia and had been undergoing treatment with allopurinol for 4 weeks. During her hospital stay, the rash intensified, and there was a worsening involvement of the mucosa in the oral and ocular area. Allopurinol was promptly discontinued, and the patient was prescribed a daily dose of 100 mg prednisolone, gradually tapering off over a 2-month period. Additionally, the treatment included anticoagulants, antibiotics, local application of mild steroid emulsions, antiseptic, and antifungal therapy for the oral mucosa. Antibiotic solutions and natural tear eye drops were used. Over the 2-month period, the rash completely resolved, and the liver enzymes returned to normal levels. CONCLUSION: DRESS syndrome is an unpredictable drug-induced reaction identified by symptoms such as rash, fever, lymphadenopathy, and potential internal organ involvement. Allopurinol is among the medications associated with this condition, particularly when there is a reduced renal clearance and simultaneous use of thiazide diuretics. Prompt withdrawal of the causative drug is the universally accepted approach to manage drug-induced hypersensitivity reactions. The use of systemic corticosteroids can reduce symptoms of delayed hypersensitivity reactions. However, the absence of randomized controlled trials leaves uncertainty about the necessity of administering steroids, sparking a controversial debate regarding their use in such cases.